Castle Biosciences’ (CSTL) Overweight Rating Reaffirmed at Stephens
Stephens reissued their overweight rating on shares of Castle Biosciences (NASDAQ:CSTL – Free Report) in a report issued on Thursday morning,Benzinga reports. They currently have a $41.00 target price on the stock. Other analysts have also recently issued research reports about the stock. Canaccord Genuity Group raised their price objective on shares of Castle Biosciences […]
More Stories
Head to Head Contrast: Innovex International (INVX) versus Its Rivals
Innovex International (NYSE:INVX – Get Free Report) is one of 25 publicly-traded companies in the “Oil & gas field machinery”...
Recruiter.com Group Appoints New CEO and Board Members
Recruiter.com Group, trading on the NASDAQ under the symbol RCRT, has recently made significant changes to its leadership team. In...
Datametrex AI (CVE:DM) Trading Up 60% – What’s Next?
Datametrex AI Limited (CVE:DM – Get Free Report)’s stock price rose 60% during trading on Monday . The stock traded...
Oracle Power (LON:ORCP) Shares Down 8.3% – Time to Sell?
Oracle Power plc (LON:ORCP – Get Free Report) was down 8.3% on Monday . The company traded as low as...
Palo Alto Networks, Inc. (NASDAQ:PANW) CEO Nikesh Arora Sells 235,492 Shares
Palo Alto Networks, Inc. (NASDAQ:PANW – Get Free Report) CEO Nikesh Arora sold 235,492 shares of the business’s stock in...
Anirudh Devgan Sells 5,920 Shares of Cadence Design Systems, Inc. (NASDAQ:CDNS) Stock
Cadence Design Systems, Inc. (NASDAQ:CDNS – Get Free Report) CEO Anirudh Devgan sold 5,920 shares of Cadence Design Systems stock...